{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:05:45Z","timestamp":1791594345845,"version":"4.3.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770161"],"award-info":[{"award-number":["81770161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00277-019-03690-2","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T19:22:58Z","timestamp":1557861778000},"page":"1627-1640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors"],"prefix":"10.1007","volume":"98","author":[{"given":"Xin","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"issue":"9","key":"3690_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/annonc\/mdq715","volume":"22","author":"MS Marcolino","year":"2011","unstructured":"Marcolino MS, Boersma E, Clementino NC, Macedo AV, Marx-Neto AD, Silva MH, van Gelder T, Akkerhuis KM, Ribeiro AL (2011) Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol 22(9):2073\u20132079","journal-title":"Ann Oncol"},{"issue":"21","key":"3690_CR2","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1002\/cncr.29587","volume":"121","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Lahoti A, O'Brien S, Nogueras-Gonz\u00e1lez GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE (2015) Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 121(21):3894\u20133904","journal-title":"Cancer"},{"issue":"10","key":"3690_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00277-018-3375-9","volume":"97","author":"M Molica","year":"2018","unstructured":"Molica M, Scalzulli E, Colafigli G, Fegatelli DA, Massaro F, Latagliata R, Fo\u00e0 R, Breccia M (2018) Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events. Ann Hematol 97(10):1803\u20131808","journal-title":"Ann Hematol"},{"issue":"5","key":"3690_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s12185-016-2071-6","volume":"104","author":"A Hino","year":"2016","unstructured":"Hino A, Yoshida H, Tada Y, Koike M, Minami R, Masaie H, Ishikawa J (2016) Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia. Int J Hematol 104(5):605\u2013611","journal-title":"Int J Hematol"},{"issue":"10","key":"3690_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.clml.2017.06.001","volume":"17","author":"JE Cortes","year":"2017","unstructured":"Cortes JE, Gambacorti-Passerini C, Kim DW, Kantarjian HM, Lipton JH, Lahoti A, Talpaz M, Matczak E, Barry E, Leip E, Br\u00fcmmendorf TH, Khoury HJ (2017) Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias. Clin Lymphoma Myeloma Leuk 17(10):684\u2013695","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"3690_CR6","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1001\/jama.2014.6634","volume":"311","author":"J Coresh","year":"2014","unstructured":"Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS (2014) Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311(24):2518\u20132531","journal-title":"JAMA"},{"issue":"9","key":"3690_CR7","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","volume":"16","author":"JP Radich","year":"2018","unstructured":"Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hobbs G, Jagasia M, Kantarjian HM, Maness L, Metheny L, Moore JO, Pallera A, Pancari P, Patnaik M, Purev E, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H (2018) Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 16(9):1108\u20131135","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"3690_CR8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884","journal-title":"Blood"},{"issue":"4","key":"3690_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1517\/14740338.4.4.689","volume":"4","author":"MA Perazella","year":"2005","unstructured":"Perazella MA (2005) Drug-induced nephropathy: an update. Expert Opin Drug Saf 4(4):689\u2013706","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"3690_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/ncpneph0076","volume":"2","author":"D Choudhury","year":"2006","unstructured":"Choudhury D, Ahmed Z (2006) Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2(2):80\u201391","journal-title":"Nat Clin Pract Nephrol"},{"issue":"9","key":"3690_CR11","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1681\/ASN.V991723","volume":"9","author":"T Miyata","year":"1998","unstructured":"Miyata T, Jadoul M, Kurokawa K, Van Ypersele de Strihou C (1998) Beta-2 microglobulin in renal disease. J Am Soc Nephrol 9(9):1723\u20131735","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3690_CR12","first-page":"139","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1):139\u2013145","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"3690_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1681\/ASN.2007050532","volume":"19","author":"J Floege","year":"2008","unstructured":"Floege J, Eitner F, Alpers CE (2008) A new look at platelet derived growth factor in renal disease. J Am Soc Nephrol 19(1):12\u201323","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3690_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0002-9440(10)63651-6","volume":"163","author":"M Takikita-Suzuki","year":"2003","unstructured":"Takikita-Suzuki M, Haneda M, Sasahara M, Owada MK, Nakagawa T, Isono M, Takikita S, Koya D, Ogasawara K, Kikkawa R (2003) Activation of Src kinase in platelet derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury. Am J Pathol 163(1):277\u2013286","journal-title":"Am J Pathol"},{"issue":"Suppl 1","key":"3690_CR15","doi-asserted-by":"publisher","first-page":"i45","DOI":"10.1093\/ndt\/gft273","volume":"29","author":"P Boor","year":"2014","unstructured":"Boor P, Ostendorf T, Floege J (2014) PDGF and the progression of renal disease. Nephrol Dial Transplant 29(Suppl 1):i45\u2013i54","journal-title":"Nephrol Dial Transplant"},{"issue":"5 Pt 1","key":"3690_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0895-7061(00)01290-5","volume":"14","author":"H Kishioka","year":"2001","unstructured":"Kishioka H, Fukuda N, Wen-Yang H, Nakayama M, Watanabe Y, Kanmatsuse K (2001) Effects of PDGF A-chain antisense oligodeoxynucleotides on growth of cardiovascular organs in stroke-prone spontaneously hypertensive rats. Am J Hypertens 14(5 Pt 1):439\u2013445","journal-title":"Am J Hypertens"},{"issue":"1","key":"3690_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/sj.ki.5001528","volume":"70","author":"C Zoja","year":"2006","unstructured":"Zoja C, Corna D, Rottoli D, Zanchi C, Abbate M, Remuzzi G (2006) Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int 70(1):97\u2013103","journal-title":"Kidney Int"},{"issue":"7","key":"3690_CR18","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1073\/pnas.89.7.2873","volume":"89","author":"T Doi","year":"1992","unstructured":"Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ (1992) Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci U S A 89(7):2873\u20132877","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03690-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03690-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03690-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T21:11:02Z","timestamp":1663449062000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03690-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["3690"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03690-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,14]]},"assertion":[{"value":"13 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}